- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03707821
Design Validation of Senofilcon A With New UV-blocking Additive
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Cupertino, California, Forente stater, 95014
- James T. Fujimoto, OD
-
-
Florida
-
Maitland, Florida, Forente stater, 32751
- Maitland Vision Center
-
Tallahassee, Florida, Forente stater, 32308
- Tallahassee Eye Center
-
-
Illinois
-
Bloomington, Illinois, Forente stater, 61701
- Eyecare Associates LLP
-
-
Kansas
-
Pittsburg, Kansas, Forente stater, 66762
- Kannarr Eye Care
-
-
Ohio
-
Granville, Ohio, Forente stater, 43023
- Procare Vision Centers
-
Westerville, Ohio, Forente stater, 43081
- Professional Vision Care, Inc
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38111
- Bradley Hines, OD
-
-
Texas
-
Tyler, Texas, Forente stater, 75703
- Frazier Vision, Inc
-
-
Wisconsin
-
New Berlin, Wisconsin, Forente stater, 53151
- Ziegler Leffingwell Eyecare
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Between 18 and 49 (inclusive) years of age at the time of informed consent.
- Eligible presbyopes will be those that wear full distance contact lenses in both eyes, then wear reading glasses over them when needed for near vision.
- The subject is a current spherical soft contact lens wearer in both eyes with a minimum of 6 hours/day and 5 days/week wear time over the last 30 days by self-report.
- Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week.
- Subjects must own a wearable pair of distance spectacles.
- The subject's vertex-corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 D (inclusive) in each eye.
- The subject's refractive cylinder must be 0.00 to -1.00 D (inclusive) in each eye.
The subject must have a spherocylindrical best corrected distance Snellen visual acuity of 20/25+3 or better in each eye.
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
- Any active or ongoing systemic disease (e.g., Sjögren's Syndrome), infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis).
- Subjects taking suspect oral medications for less than one year.
- Any prescribed or over the counter (OTC) ocular medication.
- Any known hypersensitivity or allergic reaction to Optifree® PureMoist® multi-purpose care solution or Eye-Cept® rewetting drop solution.
- Toric, extended wear, monovision or multi-focal contact lens correction.
- Any previous or planned (during the course of the study) ocular surgery (e.g., PRK, LASIK, etc.).
- Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
- Participation in clinical trials involving the Test lens within 3 months prior to study enrollment.
- Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
- Binocular vision abnormality or strabismus by self-report or prior medical history.
- History of recurrent corneal erosions, herpetic keratitis, or pathological dry eye.
- Any active ocular allergies, infections or other ocular abnormalities (entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma) that the investigator determines may interfere with the outcomes of this study or otherwise contraindicate participation in the study.
- Any Grade 2 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA Slit Lamp Classification Scale.
- Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar) within the past 3 years of otherwise successful contact lens wear.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: senofilcon A TEST Lens
Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the TEST Lens for the duration of the clinical study.
|
JJVC Investigational Contact Lens
|
Aktiv komparator: senofilcon A CONTROL Lens
Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the CONTROL Lens for the duration of the clinical study.
|
Acuvue Oasys
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Overall Comfort Score
Tidsramme: 2-Week Follow-up Evlauation
|
Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
|
2-Week Follow-up Evlauation
|
Vision Satisfaction in Bright Lighting
Tidsramme: 2-Week Follow-up Evaluation
|
Vision satisfaction in bright light was assessed using the individual item" I was satisfied with the quality of my vision in bright lighting" from the CLUE™ questionnaire.
This item used the response scale, 1: Strongly Disagree, 2: Disagree, 3: Neither Agree nor Disagree, 4: Agree and 5: Strongly Agree.
CLUE is the Contact Lens User Experience™ questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
The Proportion of responses in each category were reported for each lens type.
|
2-Week Follow-up Evaluation
|
Distance Visual Acuity
Tidsramme: 2-Week Follow-up Evlauation
|
Distance visual acuity was assessed by eye using LogMAR visual acuity at 4 meters using an ETDRS chart under high illumination high contrast conditions (room illumination > 400 lux and chart luminance 120-200 cd/m2) at the 2-week follow-up for each subject eye.
Lower values of logMAR indicate better vision, where a score of 0.0 equates to 20/20 snellen vision.
The average visual acuity for each lens was reported.
|
2-Week Follow-up Evlauation
|
Contact Lens Fitting Acceptance Rate
Tidsramme: Up to 2-Week Follow-up
|
Acceptable lens fit will be assessed at all study visits (scheduled and unscheduled) for each subject eye. Fit acceptance rate will be based on the lens fit acceptance of eyes wearing the Test lens only. Fit acceptance is a binary response where Y=1 if lens fit is acceptable and Y=0 otherwise. Unacceptable is defined as unacceptable if any one of the following criteria:
Eyes with multiple unacceptable fitting events will be counted only once. Fit rates of the Control lens will also be collected but are not a primary endpoint. |
Up to 2-Week Follow-up
|
Number of Grade 3 or Higher Slit Lamp Findings
Tidsramme: Up to 2-Week Follow-up Evlauation
|
Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e.
Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
Slit Lamp Findings will be assessed for each subject eye at all study visits (schedule and unscheduled).
SLF is a binary response where Y=1 for at least one Grade 3 or 4 slit lamp finding.
The percentage of eyes with Grade 3 or higher slit lamp findings will be analyzed and will include corneal infiltrates.
Eyes with multiple events will be counted only once.
The number of eyes with SLF with grade 3 or higher by lens was reported.
|
Up to 2-Week Follow-up Evlauation
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Overall Handling Score
Tidsramme: 2-Week Follow-up Evlauation
|
Overall handling was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
|
2-Week Follow-up Evlauation
|
Overall Quality of Vision Score
Tidsramme: 2-Week Follow-up Evlauation
|
Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
|
2-Week Follow-up Evlauation
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CR-6305
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Synsskarphet
-
VisiblyRekrutteringDigital Acuity-produktForente stater
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityRekrutteringVisual Health of Virtual RealityKina
-
University of Illinois at Urbana-ChampaignFullførtKognitiv endring | Bearbeiding, Visual SpatialForente stater
-
University of Illinois at Urbana-ChampaignAvsluttetKognitiv endring | Arbeidsminne | Hemming (psykologi) | Bearbeiding, Visual SpatialForente stater
-
New York City Health and Hospitals CorporationAvsluttetGrønn stær | Retinal sykdom | Visual Pathway DisorderForente stater
-
Neuro-Eye Diagnostic Systems, LLCNeuro-ophthalmology of Texas PLLCPåmelding etter invitasjonMakula sykdom | Visual Pathway Disorder | SynsnervesykdomForente stater
-
Cairo UniversityRekrutteringVisual for å sammenligne det visuelle resultatet mellom AcrySof™ IQ Vivity™ og TECNIS Synergy™ intraokulær linse (modell ZFR00V )Egypt
-
Fondazione G.B. Bietti, IRCCSFullførtGrønn stær | Optisk nevropati, iskemisk | Synsnerven | Visual Pathway Disorder | Nevral ledningItalia
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeGliom av lav grad | Tilbakevendende Visual Pathway Glioma | Refractory Visual Pathway Glioma | Tilbakevendende pilocytisk astrocytom i barndommen | Tilbakevendende nevrofibromatose type 1 | Refraktær nevrofibromatose type 1Forente stater
Kliniske studier på senofilcon A TEST Lens
-
Johnson & Johnson Vision Care, Inc.Fullført
-
Johnson & Johnson Vision Care, Inc.FullførtKorrigering av refraksjonsfeil | Dempning av sterkt lysForente stater
-
Coopervision, Inc.COREFullførtNærsynthetForente stater, Canada
-
Johnson & Johnson Vision Care, Inc.FullførtØyefysiologiForente stater
-
Johnson & Johnson Vision Care, Inc.Fullført
-
Johnson & Johnson Vision Care, Inc.Fullført
-
Coopervision, Inc.FullførtAstigmatisme BilateralCanada
-
Johnson & Johnson Vision Care, Inc.FullførtSynsforstyrrelserForente stater
-
Johnson & Johnson Vision Care, Inc.Fullført
-
Johnson & Johnson Vision Care, Inc.FullførtUtgått kontaktlinsebrukForente stater